Shiloh
Editor, Senior Moderator
Source: https://www.cidrap.umn.edu/news-perspective/2021/11/stewardship-resistance-scan-nov-10-2021
Stewardship / Resistance Scan for Nov 10, 2021
AMR industry progress report; Vaccines, monoclonal antibodies for AMR
Filed Under:
Antimicrobial Stewardship
AMR Industry Alliance report highlights progress, challenges
A new report from the AMR Industry Alliance (AMRIA) highlights some of the efforts that life sciences companies are pursuing to deliver on commitments to tackle antimicrobial resistance.
The 2021 AMRIA Progress Report draws on a survey completed by 53 alliance members and looks at efforts across four strategic pillars—research and science, access, appropriate use, and manufacturing and the environment.
The survey showed that AMRIA members invested $1.8 to $1.9 billion in antimicrobial resistance (AMR)-relevant research and development (R&D) in financial years 2019 and 2020 and contributed to R&D on 93 products, including 54 antibiotics, 12 vaccines, 13 diagnostic platforms, and 14 non-traditional products. Eighty-one percent of surveyed companies actively supported access to AMR-relevant products and technologies.
Support for appropriate use and appropriate manufacturing was strong as well. Overall, 92% of pharmaceutical companies, 89% of generics companies, and 80% of diagnostics companies have implemented appropriate use and stewardship activities, while 76% of manufacturing sites owned by alliance members have fully met all requirements for the Common Antibiotic Manufacturing Framework, and 98% have partially met the requirements.
The report also highlights the continuing challenges, however. Overall, 80% of AMRIA members said they were actively engaged in efforts to strengthen financial incentives to stimulate antibiotic development. But those efforts in are in the early stages of implementation, and 32% percent of alliance members said they expected to reduce their investments in AMR-related R&D if market conditions don't improve for antibiotic development. And only 51% of members reported collecting and/or sharing surveillance data to generate evidence to support appropriate use and stewardship.
AMRIA, formed in 2017, represents a coalition of 93 biotechnology, diagnostics, generics, and large research-based biopharmaceutical companies and associations. The survey was conducted by RAND Europe.
Nov 9 AMRIA 2021 Progress Report executive summary
Project focuses on vaccines, monoclonal antibodies to fight AMR
A coalition of academic researchers and industry partners yesterday announced a new public-private partnership to use artificial intelligence and big data to unlock the potential of vaccines and monoclonal antibodies to fight AMR.
The primary goal of PrIMAVeRa (Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance) is to develop an open-sourced, web-based platform that combines mathematical models with health and economic data to predict how much vaccines and monoclonal antibodies could reduce AMR and help policymakers determine which specific vaccines and monoclonal antibodies should be prioritized. The initiative involves 19 partners in the European Union, United Kingdom, and Russia.
Leaders of the initiative say the lack of such data-driven tools has discouraged investment in the development of vaccines and monoclonal antibodies against drug-resistant pathogens.
"This is a highly innovative project that will highlight the important, but often forgotten role that vaccines can play in combatting AMR," Ole F. Olesen, executive director of the European Vaccine Initiative, said in a press release.
PrIMAVeRa is being backed by €9 million (US $10.3 million) from the Innovative Medicines Initiative 2.
Nov 9 European Vaccine Initiative press release
Stewardship / Resistance Scan for Nov 10, 2021
AMR industry progress report; Vaccines, monoclonal antibodies for AMR
Filed Under:
Antimicrobial Stewardship
AMR Industry Alliance report highlights progress, challenges
A new report from the AMR Industry Alliance (AMRIA) highlights some of the efforts that life sciences companies are pursuing to deliver on commitments to tackle antimicrobial resistance.
The 2021 AMRIA Progress Report draws on a survey completed by 53 alliance members and looks at efforts across four strategic pillars—research and science, access, appropriate use, and manufacturing and the environment.
The survey showed that AMRIA members invested $1.8 to $1.9 billion in antimicrobial resistance (AMR)-relevant research and development (R&D) in financial years 2019 and 2020 and contributed to R&D on 93 products, including 54 antibiotics, 12 vaccines, 13 diagnostic platforms, and 14 non-traditional products. Eighty-one percent of surveyed companies actively supported access to AMR-relevant products and technologies.
Support for appropriate use and appropriate manufacturing was strong as well. Overall, 92% of pharmaceutical companies, 89% of generics companies, and 80% of diagnostics companies have implemented appropriate use and stewardship activities, while 76% of manufacturing sites owned by alliance members have fully met all requirements for the Common Antibiotic Manufacturing Framework, and 98% have partially met the requirements.
The report also highlights the continuing challenges, however. Overall, 80% of AMRIA members said they were actively engaged in efforts to strengthen financial incentives to stimulate antibiotic development. But those efforts in are in the early stages of implementation, and 32% percent of alliance members said they expected to reduce their investments in AMR-related R&D if market conditions don't improve for antibiotic development. And only 51% of members reported collecting and/or sharing surveillance data to generate evidence to support appropriate use and stewardship.
AMRIA, formed in 2017, represents a coalition of 93 biotechnology, diagnostics, generics, and large research-based biopharmaceutical companies and associations. The survey was conducted by RAND Europe.
Nov 9 AMRIA 2021 Progress Report executive summary
Project focuses on vaccines, monoclonal antibodies to fight AMR
A coalition of academic researchers and industry partners yesterday announced a new public-private partnership to use artificial intelligence and big data to unlock the potential of vaccines and monoclonal antibodies to fight AMR.
The primary goal of PrIMAVeRa (Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance) is to develop an open-sourced, web-based platform that combines mathematical models with health and economic data to predict how much vaccines and monoclonal antibodies could reduce AMR and help policymakers determine which specific vaccines and monoclonal antibodies should be prioritized. The initiative involves 19 partners in the European Union, United Kingdom, and Russia.
Leaders of the initiative say the lack of such data-driven tools has discouraged investment in the development of vaccines and monoclonal antibodies against drug-resistant pathogens.
"This is a highly innovative project that will highlight the important, but often forgotten role that vaccines can play in combatting AMR," Ole F. Olesen, executive director of the European Vaccine Initiative, said in a press release.
PrIMAVeRa is being backed by €9 million (US $10.3 million) from the Innovative Medicines Initiative 2.
Nov 9 European Vaccine Initiative press release